Trial Profile
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Systemic scleroderma
- Focus Registrational; Therapeutic Use
- Acronyms focuSSced
- Sponsors Chugai Pharmaceutical; Roche
- 31 Aug 2023 Results assessing biomarkers of fibrosis, inflammation, and extracellular matrix , published in the Clinical Immunology
- 19 May 2021 Results of a post hoc analysis assessing the safety and efficacy of a subset of patients who had Systemic Sclerosis Interstitial Lung Disease at baseline, as evidenced by high-resolution computed tomography presented at the 117th International Conference of the American Thoracic Society
- 19 May 2021 Results (n=136) of post-hoc analyses assessing the SSc-ILD at baseline, high-resolution computed tomography, Lung function assessed by change from baseline to week 48 in absolute forced vital capacity and percent-predicted forced vital capacity in patients with SSc-ILD, presented at the 117th International Conference of the American Thoracic Society.